Zhiqiang Mo

571 total citations
23 papers, 466 citations indexed

About

Zhiqiang Mo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Zhiqiang Mo has authored 23 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Zhiqiang Mo's work include Cancer Diagnosis and Treatment (6 papers), Management of metastatic bone disease (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Zhiqiang Mo is often cited by papers focused on Cancer Diagnosis and Treatment (6 papers), Management of metastatic bone disease (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Zhiqiang Mo collaborates with scholars based in China and United States. Zhiqiang Mo's co-authors include Manran Liu, Yimeng Wang, Zhenhua Li, Guanglun Yang, Haojun Luo, Gang Tu, Fangfang Yang, Junjie Bao, Mingli Han and Xin Chen and has published in prestigious journals such as Journal of Clinical Oncology, Neuroscience and Oncotarget.

In The Last Decade

Zhiqiang Mo

21 papers receiving 464 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhiqiang Mo China 10 246 204 153 86 68 23 466
Li‐Yan Khor United States 13 244 1.0× 143 0.7× 173 1.1× 45 0.5× 339 5.0× 13 532
Danielle P. Johnson United States 5 273 1.1× 99 0.5× 97 0.6× 22 0.3× 54 0.8× 7 387
Hy-De Lee South Korea 12 115 0.5× 157 0.8× 228 1.5× 36 0.4× 61 0.9× 16 411
Magdalena Orzechowska Poland 11 196 0.8× 132 0.6× 116 0.8× 47 0.5× 120 1.8× 34 407
Maria Hassan Pakistan 7 273 1.1× 68 0.3× 245 1.6× 18 0.2× 57 0.8× 19 479
Christos Mikropoulos United Kingdom 11 175 0.7× 101 0.5× 286 1.9× 41 0.5× 179 2.6× 21 483
Sheng Ye China 15 283 1.2× 182 0.9× 208 1.4× 14 0.2× 131 1.9× 36 585
Zhanhuai Wang China 12 231 0.9× 170 0.8× 243 1.6× 20 0.2× 68 1.0× 24 501
Weimin Mao China 12 335 1.4× 272 1.3× 93 0.6× 27 0.3× 126 1.9× 28 558

Countries citing papers authored by Zhiqiang Mo

Since Specialization
Citations

This map shows the geographic impact of Zhiqiang Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhiqiang Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhiqiang Mo more than expected).

Fields of papers citing papers by Zhiqiang Mo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhiqiang Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhiqiang Mo. The network helps show where Zhiqiang Mo may publish in the future.

Co-authorship network of co-authors of Zhiqiang Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Zhiqiang Mo. A scholar is included among the top collaborators of Zhiqiang Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhiqiang Mo. Zhiqiang Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mo, Zhiqiang, Qiao Li, Jian He, et al.. (2024). Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapy. Journal for ImmunoTherapy of Cancer. 12(1). e008191–e008191. 3 indexed citations
3.
4.
Chen, Zide, Qi Wang, Feng Shi, et al.. (2022). CircPOLR2A Promotes Proliferation and Impedes Apoptosis of Glioblastoma Multiforme Cells by Up-regulating POU3F2 to Facilitate SOX9 Transcription. Neuroscience. 503. 118–130. 3 indexed citations
5.
6.
Chen, Song, et al.. (2021). Real-world efficacy and safety of lenvatinib-base therapy for patients with unresectable hepatocellular carcinoma in China: A multicenter retrospective analysis.. Journal of Clinical Oncology. 39(15_suppl). e16192–e16192. 1 indexed citations
7.
8.
Zhang, Tao, et al.. (2021). 125I Seed Promotes Apoptosis in Non-small Lung Cancer Cells via the p38 MAPK-MDM2-p53 Signaling Pathway. Frontiers in Oncology. 11. 582511–582511. 10 indexed citations
9.
10.
Wang, Lifei, Zhiqiang Mo, Yanling Zhang, et al.. (2020). Clinical efficacy and prognostic factors of CT-guided 125I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes. Cancer Imaging. 20(1). 25–25. 7 indexed citations
11.
Mo, Zhiqiang, et al.. (2020). Feasibility and clinical value of computed tomography-guided 125I brachytherapy for pain palliation in patients with retroperitoneal lymph node metastases. Journal of Cancer Research and Therapeutics. 16(2). 372–378. 3 indexed citations
12.
Shi, Feng, Zhiqiang Mo, Wei Cui, et al.. (2020). Microwave ablation after downstaging of hepatocellular carcinoma: outcome was similar to tumor within Milan criteria. European Radiology. 30(5). 2454–2462. 20 indexed citations
13.
Mo, Zhiqiang, et al.. (2020). Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 38(15_suppl). e16603–e16603. 9 indexed citations
14.
Mo, Zhiqiang, Jian He, & Xiaohong Chen. (2019). Feasibility and Clinical Value of CT-Guided 125I Brachytherapy for Metastatic Soft Tissue Sarcoma after First-Line Chemotherapy Failure. Brachytherapy. 18(3). S85–S85. 13 indexed citations
15.
16.
Mo, Zhiqiang, et al.. (2017). CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. Journal of Cancer. 8(11). 2104–2113. 20 indexed citations
17.
Zhong, Zhihui, et al.. (2016). CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region. Translational Oncology. 10(1). 90–98. 5 indexed citations
18.
Mo, Zhiqiang, Guohong Li, Zhihui Zhong, et al.. (2016). 125I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments. Oncotarget. 7(14). 18384–18393. 13 indexed citations
19.
20.
Liu, Manran, Yimeng Wang, Zhiqiang Mo, et al.. (2011). Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Molecular and Cellular Biochemistry. 363(1-2). 427–436. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Li‐Yan Khor Breakdown of academic impact, for papers by Danielle P. Johnson Breakdown of academic impact, for papers by Hy-De Lee Breakdown of academic impact, for papers by Magdalena Orzechowska Breakdown of academic impact, for papers by Maria Hassan Breakdown of academic impact, for papers by Christos Mikropoulos Breakdown of academic impact, for papers by Sheng Ye Breakdown of academic impact, for papers by Zhanhuai Wang Breakdown of academic impact, for papers by Weimin Mao
Rankless by CCL
2026